Abstracts tagged "T Cell"

Abstract Number: 0803 • ACR Convergence 2023
IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome
Matthew Eremita¹, Omar Geier², Joyce Hui-Yuen¹ and Matthew Taylor³, ¹Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, ³Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 0073 • ACR Convergence 2023
PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
Sofie Rask¹, Christian Andersen², Malene Hvid¹, Kim Ravnskjær², Bent Deleuran¹ and Stinne Greisen³, ¹Aarhus University, Aarhus, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Programmed death 1 (PD-1) is an immune checkpoint receptor expressed by activated T cells, and of major importance in maintaining peripheral tolerance. Expression of…
Abstract Number: 0094 • ACR Convergence 2023
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Helena Jonsson¹, Carlos Donado², Erin Theisen², Dominique Jones¹, Aparna Nathan³, Fan Zhang⁴, Accelerating Medicines Partnership (AMP): RA/SLE¹, Soumya Raychaudhuri¹ and Michael Brenner², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴University of Colorado, Aurora, CO
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
Abstract Number: 0804 • ACR Convergence 2023
Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Leah M. Huey¹, Emily Vance¹, Holly L. Rosenzweig², Bryce Binstadt³ and Ruth J. Napier², ¹Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, VA Portland Health Care System, Portland, OR, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Microbial sensing molecule nucleotide-binding oligomerization-domain containing protein 2 (NOD2) is expressed by CD4+ T cells and plays a novel T cell-intrinsic role within CD4+…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…
Abstract Number: 0074 • ACR Convergence 2023
Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects
Yevgeniya Orlovsky, Melissa Swiecki, Kimberly Colby, Changbao Liu, Josephine Wixted, Olesya Chornoguz, Navin Rao, Edith Janssen and Ling-Yang Hao, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: T cells play an important role in the development and progression of many autoimmune diseases. Inhibition of T cells and their effector mechanisms has…
Abstract Number: 0095 • ACR Convergence 2023
Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE
Thomas Winans¹, Nick Huang¹, Joshua Lewis¹, Xiaojing Wang¹, Tamas Faludi¹, Daniel Krakko², Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²North Carolina State University, Raleigh, NC, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY
Background/Purpose: The kynurenine (KYN) pathway has been linked to disease pathogenesis in patients with systemic lupus erythematosus (SLE) (https://pubmed.ncbi.nlm.nih.gov/26366134/). Genetically enforced overexpression of Rab4A activates…
Abstract Number: 0886 • ACR Convergence 2023
Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation
Tarin Bigley¹, Eden Xue¹, Lifei Zhu¹, Li-ping Yang¹ and wayne Yokoyama², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO
Background/Purpose: Viral infections have been implicated as major factors in autoimmune disease but demonstrating causality is often challenging. We found that neonatal infection with a…
Abstract Number: 1580 • ACR Convergence 2023
CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon
Calvin Law¹, Vanessa Wacleche², Ye Cao³, Arundhati Pillai¹, Alice Horisberger⁴, Sabrina Bracero³, Viktoriya Skidanova³, Zhihan Li³, Ifeoluwakiisi Adejoorin², Isaac Benque³, Diana Pena Nunez³, Daimon Simmons², Joshua Keegan⁴, Lin Chen³, John Sowerby³, Accelerating Medicines Partnership (AMP): RA/SLE², Elena Massarotti², Karen Costenbader⁴, Michael Brenner⁴, James Lederer⁴, Judd Hultquist¹, Jaehyuk Choi¹ and Deepak Rao², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Expansion of B cell-helper T cells including T follicular helper (Tfh) and T peripheral helper (Tph) cells is a prominent feature of systemic lupus…
Abstract Number: 0076 • ACR Convergence 2023
Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
AASTHA KHULLAR¹, Varun Dhir², Leishangthem Bidyalaxmi¹, Chandra Bhushan Prasad³, Sankar Jayaprakash¹, Siddharth Jain⁴, Biman Saikia¹, Aman Sharma⁵, Shefali Sharma⁶, Ashok Kumar Yadav¹, Shankar Naidu¹ and Sanjay Jain⁷, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴AIIMS, Delhi, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India, ⁶PGIMER< Chandigarh, Chandigarh, India, ⁷Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Background: GMCSF producing T-cells may be implicated in the pathogenesis of autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriatic arthritis. Few…
Abstract Number: 0114 • ACR Convergence 2023
Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
Yu Shi¹, Xiaofan Luo², Quan Chen³, Jiuliang zhao⁴, Mengtao Li⁴ and xiaofeng Zeng⁵, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Nankai University, Tianjin, China, ³Nankai University, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
Abstract Number: 0909 • ACR Convergence 2023
Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Joy Park¹, Xiaojing Wang², Aparna Godavarthy¹, Akshay Patel², Krakko Daniel¹, Jessica Nolan¹, Joanne Chilton¹, Bryan Blaker¹ and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 1689 • ACR Convergence 2023
Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy
Lihi Eder¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, Liqun Diao² and Vinod Chandran⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features;…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].